Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1646
This examiner grants 54% of resolved cases
Estella M. Gustilo serves in Tech Center 1600 and Art Unit 1644. The profile includes 69 resolved cases, which show an allowance rate of 53.6 percent. This 53.6 percent rate provides a baseline for practitioners to estimate the probability of a grant. With 69 resolved cases, the data provides a look at the examiner's tendencies in this biotechnology and organic chemistry center.
The data shows an interview lift of 34.5 percent. This figure indicates that conducting an interview is associated with an increased probability of allowance compared to the baseline of cases where no interview occurs. Practitioners may consider the 34.5 percent lift when deciding whether to engage in direct communication. This positive lift suggests that verbal advocacy is a significant factor in the prosecution process for Art Unit 1644.
The median days to allowance for Gustilo is 1279. This 1279-day timeline provides a benchmark for the expected duration of the prosecution process from filing to grant. The combination of the 53.6 percent allowance rate and the 34.5 percent interview lift offers a roadmap for applicants. Understanding these metrics, including the 1279-day median, helps in setting expectations for both timing and results in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18052172 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF GPRC5DXCD3 BISPECIFIC ANTIBODIES | Final Rejection | Janssen Biotech, Inc. |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | Non-Final OA | Janssen Biotech, Inc. |
| 18799503 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR BLADDER CANCER | Non-Final OA | Genentech, Inc. |
| 18416031 | Anti-Jagged1 Antibodies and Methods of Use | Non-Final OA | Genentech, Inc. |
| 17605798 | FUSION POLYPEPTIDE COMPRISING Fc REGION OF IMMUNOGLOBULIN AND GDF15 | Final Rejection | LG CHEM, LTD. |
| 17284284 | EXTRACELLULAR VESICLES FOR TARGETED THERAPIES AGAINST MYELOID-DERIVED SUPPRESSOR CELLS | Final Rejection | Ohio State Innovation Foundation |
| 17507414 | METHODS OF TREATING CROHN'S DISEASE | Non-Final OA | ELI LILLY AND COMPANY |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | Non-Final OA | WUXI BIOLOGICS IRELAND LIMITED |
| 18484631 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES | Non-Final OA | Merck Sharp & Dohme LLC |
| 18695945 | PEANUT ALLERGY EPITOPE | Non-Final OA | Vanderbilt University |
| 18818268 | ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME | Final Rejection | The General Hospital Corporation |
| 18453098 | FCRN BINDING POLYPEPTIDES | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17818854 | METHODS OF INCREASING RESPONSE TO CANCER RADIATION THERAPY | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18692039 | MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES | Non-Final OA | YEDA RESEARCH AND DEVELOPMENT CO. LTD. |
| 18696689 | MULTISPECIFIC BINDING AGENTS AGAINST PD-L1 AND CD137 IN COMBINATION THERAPY | Non-Final OA | BioNTech SE |
| 18630379 | Optimized CD3 Antigen Binding Domains | Non-Final OA | MedImmune, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy